Menu Search
Equities

Laboratorio Farmaceutico Erfo SpA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RK7:FRA

Laboratorio Farmaceutico Erfo SpA

Actions
  • Price (EUR)1.13
  • Today's Change-0.04 / -3.42%
  • Shares traded2.00k
  • 1 Year change-4.24%
  • Beta1.0239
Data delayed at least 15 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

  • Revenue in EUR (TTM)7.68m
  • Net income in EUR387.72k
  • Incorporated2010
  • Employees47.00
  • Location
    Laboratorio Farmaceutico Erfo SpAViale Geki RussoZona Artigianale Loc. PontegalloVILLAFRANCA TIRRENA 98049ItalyITA
  • Websitehttps://www.erfo.it/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.